<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="letter" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Mol Genet Metab Rep</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol Genet Metab Rep</journal-id>
<journal-title-group>
<journal-title>Molecular Genetics and Metabolism Reports</journal-title>
</journal-title-group>
<issn pub-type="epub">2214-4269</issn>
<publisher>
<publisher-name>Elsevier</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28053875</article-id>
<article-id pub-id-type="pmc">5198857</article-id>
<article-id pub-id-type="publisher-id">S2214-4269(16)30137-9</article-id>
<article-id pub-id-type="doi">10.1016/j.ymgmr.2016.12.007</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Correspondence</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Phenotypic heterogeneity of a compound heterozygous <italic>SUCLA2</italic> mutation<sup><xref ref-type="fn" rid="d31e556">☆</xref></sup><sup><xref ref-type="fn" rid="d31e561">☆☆</xref></sup><sup><xref ref-type="fn" rid="d31e566">☆☆☆</xref></sup></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Finsterer</surname>
<given-names>Josef</given-names>
</name>
<email>fifigs1@yahoo.de</email>
<xref ref-type="aff" rid="af0005">a</xref>
<xref ref-type="corresp" rid="cr0005">⁎</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zarrouk-Mahjoub</surname>
<given-names>Sinda</given-names>
</name>
<xref ref-type="aff" rid="af0010">b</xref>
</contrib>
</contrib-group>
<aff id="af0005"><label>a</label>Krankenanstalt Rudolfstiftung, Vienna, Austria</aff>
<aff id="af0010"><label>b</label>University of Tunis El Manar, Genomics Platform, Pasteur Institute of Tunis, Tunisia</aff>
<author-notes>
<corresp id="cr0005"><label>⁎</label>Corresponding author at: Postfach 20, 1180 Vienna, Austria.Postfach 20Vienna1180Austria <email>fifigs1@yahoo.de</email></corresp>
</author-notes>
<pub-date pub-type="pmc-release">
<day>23</day>
<month>12</month>
<year>2016</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
<pub-date pub-type="collection">
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>23</day>
<month>12</month>
<year>2016</year>
</pub-date>
<volume>10</volume>
<fpage>31</fpage>
<lpage>32</lpage>
<history>
<date date-type="received">
<day>18</day>
<month>12</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>12</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>© 2016 The Authors</copyright-statement>
<copyright-year>2016</copyright-year>
<license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">
<license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p>
</license>
</permissions>
<kwd-group id="ks0005">
<title>Keywords</title>
<kwd>mtDNA</kwd>
<kwd>M.9155A &gt; G</kwd>
<kwd>Deafness</kwd>
<kwd>Diabetes</kwd>
<kwd>Gene</kwd>
<kwd>Mitochondrial disorder</kwd>
<kwd>Stroke-like episode</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p content-type="salutation">Letter to the Editor</p>
<p>With interest we read the article by Huang et al. about two siblings carrying both the same compound heterozygous <italic>SUCLA2</italic> mutation, which manifested phenotypically with a progressive multisystem syndrome, resulting in severe disability (patient-1) or death (patient-2) <xref ref-type="bibr" rid="bb0005">[1]</xref>. We have the following comments and concerns.</p>
<p>Patient-1 was treated with dichloroacetate (DCA) over at least 4y. DCA is well-known for its neurotoxicity in MELAS patients, resulting in severe polyneuropathy <xref ref-type="bibr" rid="bb0010">[2]</xref>. To which degree was the continuous deterioration of the phenotype attributable to the mitochondrion-toxic effect of DCA? Was polyneuropathy by age 1y attributed to the <italic>SUCLA2</italic> mutation or interpreted as side effect of DCA? Was polyneuropathy a complication of diabetes?</p>
<p>Ketogenic diet has been shown to be highly beneficial for epilepsy, migraine, autism, or myopathy in single patients with a mitochondrial disorder (MID) <xref ref-type="bibr" rid="bb0015">[3]</xref>. Ketogenic diet may even improve cerebral lesions on MRI in Leigh syndrome <xref ref-type="bibr" rid="bb0020">[4]</xref>. Why was a ketogenic diet not applied to patient-1 but only to patient-2? Was ketogenic diet in patient-2 beneficial?</p>
<p>Patient-1 had normal cerebral MRI at age 3m and callosal thinning at age 7m. Why was no further MRI carried out during the next 13y despite obvious progression of cerebral involvement (<xref ref-type="table" rid="t0005">Table 1</xref>)?</p>
<p>Were bone fractures in both patients spontaneous or traumatic? Was a densitometry carried out? Which were the calcium, phosphate, and hormone levels in both patients? Was multiple hormone deficiency attributed to hypopituitarism? Was there a pituitary adenoma?</p>
<p>MID patients frequently develop cardiac disease, which may be subclinical at onset <xref ref-type="bibr" rid="bb0025">[5]</xref>. Which were the results of long-term ECG and echocardiography when actively searching for cardiac involvement?</p>
<p>Overall, this interesting study could be strengthened by reporting why DCA was given for 4y (patient-1), why no ketogenic diet was tried (patient-1), if there was a pituitary adenoma, and how cerebral involvement progressed on MRI (patient-1).</p>
</body>
<back>
<ref-list id="bi0005">
<title>References</title>
<ref id="bb0005">
<label>1</label>
<element-citation id="rf0005" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Bedoyan</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Demirbas</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Miron</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Edelheit</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Grahame</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>DeBrosse</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Hoppel</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Kerr</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Anselm</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Berry</surname>
<given-names>G.T.</given-names>
</name>
</person-group>
<article-title>Succinyl-CoA synthetase (SUCLA2) deficiency in two siblings with impaired activity of other mitochondrial oxidative enzymes in skeletal muscle without mitochondrial DNA depletion</article-title>
<source/>Mol. Genet. Metab.
          <year>2016</year>
<comment>(pii: S1096-7192(16)30314-6, Nov 12)</comment>
</element-citation>
</ref>
<ref id="bb0010">
<label>2</label>
<element-citation id="rf0010" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaufmann</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Engelstad</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jhung</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sano</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Shungu</surname>
<given-names>D.C.</given-names>
</name>
<name>
<surname>Millar</surname>
<given-names>W.S.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Gooch</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Pascual</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Hirano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Stacpoole</surname>
<given-names>P.W.</given-names>
</name>
<name>
<surname>DiMauro</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>De Vivo</surname>
<given-names>D.C.</given-names>
</name>
</person-group>
<article-title>Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial</article-title>
<source/>Neurology
          <volume>66</volume>
<year>2006</year>
<fpage>324</fpage>
<lpage>330</lpage>
<pub-id pub-id-type="pmid">16476929</pub-id>
</element-citation>
</ref>
<ref id="bb0015">
<label>3</label>
<element-citation id="rf0015" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steriade</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Andrade</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Faghfoury</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tarnopolsky</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Tai</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS) may respond to adjunctive ketogenic diet</article-title>
<source/>Pediatr. Neurol.
          <volume>50</volume>
<year>2014</year>
<fpage>498</fpage>
<lpage>502</lpage>
<pub-id pub-id-type="pmid">24656211</pub-id>
</element-citation>
</ref>
<ref id="bb0020">
<label>4</label>
<element-citation id="rf0020" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wijburg</surname>
<given-names>F.A.</given-names>
</name>
<name>
<surname>Barth</surname>
<given-names>P.G.</given-names>
</name>
<name>
<surname>Bindoff</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Birch-Machin</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>van der Blij</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Ruitenbeek</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Turnbull</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Schutgens</surname>
<given-names>R.B.</given-names>
</name>
</person-group>
<article-title>Leigh syndrome associated with a deficiency of the pyruvate dehydrogenase complex: results of treatment with a ketogenic diet</article-title>
<source/>Neuropediatrics
          <volume>23</volume>
<year>1992</year>
<fpage>147</fpage>
<lpage>152</lpage>
<pub-id pub-id-type="pmid">1641082</pub-id>
</element-citation>
</ref>
<ref id="bb0025">
<label>5</label>
<element-citation id="rf0025" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Finsterer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kothari</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Cardiac manifestations of primary mitochondrial disorders</article-title>
<source/>Int. J. Cardiol.
          <volume>177</volume>
<year>2014</year>
<fpage>754</fpage>
<lpage>763</lpage>
<pub-id pub-id-type="pmid">25465824</pub-id>
</element-citation>
</ref>
</ref-list>
<fn-group>
<fn id="d31e556">
<label>☆</label>
<p id="np0005">There are no conflicts of interest.</p>
</fn>
<fn id="d31e561">
<label>☆☆</label>
<p id="np0010">Both authors contributed equally.</p>
</fn>
<fn id="d31e566">
<label>☆☆☆</label>
<p id="np0015">No funding was received.</p>
</fn>
</fn-group>
</back>
<floats-group>
<table-wrap id="t0005" position="float">
<label>Table 1</label>
<caption>
<p>Phenotypic manifestations of SUCLA2 mutations in the present and previous studies.</p>
</caption>
<alt-text id="al0005">Table 1</alt-text>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th>Phenotype</th>
<th>Patient 1</th>
<th>Patient 2</th>
<th>Previously reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>CNS involvement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td> Encephalopathy</td>
<td>Yes</td>
<td>Yes</td>
<td>[Lamperti 2012]</td>
</tr>
<tr>
<td> Dystonia</td>
<td>Yes</td>
<td>Yes</td>
<td>[Carrozza 2016]</td>
</tr>
<tr>
<td> Spasticity</td>
<td>Yes</td>
<td>Yes</td>
<td>[Carrozza 2016]</td>
</tr>
<tr>
<td> Choreoathetosis</td>
<td>Yes</td>
<td>No</td>
<td>[Ostergaard 2007]</td>
</tr>
<tr>
<td> Migraine</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td> Developmental delay</td>
<td>Yes</td>
<td>Yes</td>
<td>[Carrozza 2016]</td>
</tr>
<tr>
<td> Irritability</td>
<td>Yes</td>
<td>No</td>
<td>[Lamperti 2012]</td>
</tr>
<tr>
<td> Hypotonia</td>
<td>Yes</td>
<td>Yes</td>
<td>[Carrozza 2016]</td>
</tr>
<tr>
<td> Perturbed sleep/wake cycle</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td> Dysarthria/anarthria</td>
<td>Yes</td>
<td>Yes</td>
<td>[Lamperti 2012]</td>
</tr>
<tr>
<td> Basal ganglia involvement</td>
<td>Yes</td>
<td>No</td>
<td>[Carrozzo 2016, Liu 2014]</td>
</tr>
<tr>
<td> Epilepsy</td>
<td>No</td>
<td>No</td>
<td>[Carrozza 2016]</td>
</tr>
<tr>
<td> Corpus callosum thinning</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td> Low-lying conus medullaris</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td> Leigh-like MRI</td>
<td>No</td>
<td>Yes</td>
<td>[Wortmann 2009]</td>
</tr>
<tr>
<td>Ocular involvement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td> Blindness (optic atrophy)</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Otologic involvement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td> Hearing loss</td>
<td>Yes</td>
<td>Yes</td>
<td>[Morawa 2009, Carrozza 2016]</td>
</tr>
<tr>
<td>Gastrointestinal involvement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td> Cyclic vomiting</td>
<td>Yes</td>
<td>Yes</td>
<td>[Carrozza 2016]</td>
</tr>
<tr>
<td> Constipation</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td> Gastroparesis</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td> Gastro-intestinal dysmotility</td>
<td>No</td>
<td>Yes</td>
<td>[Lamperti 2012]</td>
</tr>
<tr>
<td> Cecal volvulus</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td> GERD</td>
<td>Yes</td>
<td>Yes</td>
<td>[Carrozza 2016]</td>
</tr>
<tr>
<td> Poor feeding</td>
<td>Yes</td>
<td>Yes</td>
<td>[Carrozza 2016]</td>
</tr>
<tr>
<td> Gallstones</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Endocrine involvement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td> Diabetes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td> Short stature</td>
<td>Yes</td>
<td>Yes</td>
<td>[Carrozza 2016]</td>
</tr>
<tr>
<td> Hypogonadism</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td> Osteoporosis (spontaneous fractures)</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td> Hyperhidrosis</td>
<td>No</td>
<td>No</td>
<td>[Carrozza 2016, Ostergaard 2007]</td>
</tr>
<tr>
<td>Peripheral nerve involvement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td> Polyneuropathy</td>
<td>Yes</td>
<td>Yes</td>
<td>[Carrozza 2007]</td>
</tr>
<tr>
<td>Muscle involvement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td> Myopathy</td>
<td>Yes</td>
<td>Yes</td>
<td>[Carrozza 2016]</td>
</tr>
<tr>
<td> Ptosis</td>
<td>Yes</td>
<td>Yes</td>
<td>[Carrozza 2016]</td>
</tr>
<tr>
<td> Facial weakness</td>
<td>Yes</td>
<td>Yes</td>
<td>[Liu 2014]</td>
</tr>
<tr>
<td> Ophthalmoparesis</td>
<td>Yes</td>
<td>Yes</td>
<td>[Carrozzas 2016]</td>
</tr>
<tr>
<td>Bone marrow involvement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td> Anemia</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td> Thrombocytopenia</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Pulmonary involvement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td> Chronic reactive airway disease</td>
<td>Yes</td>
<td>No</td>
<td>[Carrozzas 2016]</td>
</tr>
<tr>
<td>Others</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td> Cardiomyopathy</td>
<td>No</td>
<td>No</td>
<td>[Carrozzo 2007]</td>
</tr>
<tr>
<td> Sacral dimple</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td> Immunodeficiency</td>
<td>No</td>
<td>Yes</td>
<td>[Carrozza 2016]</td>
</tr>
<tr>
<td> Dysmorphism</td>
<td>No</td>
<td>No</td>
<td>[Carrozza 2016]</td>
</tr>
<tr>
<td> Fanconi syndrome</td>
<td>No</td>
<td>No</td>
<td>[Carrozza 2007]</td>
</tr>
<tr>
<td> Lactic acidosis</td>
<td>Yes</td>
<td>Yes</td>
<td>[Liu 2014]</td>
</tr>
<tr>
<td> Methylmalonic academia (UOA)</td>
<td>Yes</td>
<td>Yes</td>
<td>[Liu 2014]</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>GERD: gastro-enterological reflux disease, UOA: urine organic acids.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>